Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine
12.10.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers. The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1.
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer. The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
1 Funding reference number FKZ 13GW0451A+B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 13:07:00 EEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX3.9.2026 13:05:00 EEST | Press release
LITEON Technology (2301.TW) today announced a strategic investment in DCX POLSKA Sp. z o.o. (“DCX Liquid Cooling Systems”), a Warsaw, Poland-based provider of advanced liquid cooling systems for AI and High-Performance Computing (HPC) data centers. Upon closing of the transaction, LITEON will hold approximately 25% equity ownership in DCX Liquid Cooling Systems with a total transaction value of approximately US$176 million. The investment brings together DCX's deep expertise in liquid cooling technologies, including coolant distribution units (CDUs), facility coolant distribution units (FDUs), cold plates and immersion cooling systems, with LITEON's strengths in AI server power management, rack-level power delivery and 800VDC power architectures. Together, the two companies are positioned to deliver highly integrated power and thermal management solutions for the rapidly evolving AI infrastructure and next-generation high-density computing market. This press release features multimedia
The Untold Story ‘NEW YORK IN MONCLER’3.9.2026 13:00:00 EEST | Press release
The untold story of New York in Moncler began when snow met concrete. What could have melted instead endured, forging a love built on pioneering moments and strengthened with every chapter. They found each other, again and again. Decades later, their story is finally ready to be shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903671495/en/ NEW YORK IN MONCLER MIDTOWN MOUNTAINS Revealed through one of the largest open-air public exhibitions the city has ever seen, New York in Monclerunveils the peak moments that capture the bond between New York and Moncler, transforming communal spaces across the city into a powerful retrospective gallery from September 9-13. New York in Moncleris a very public display of affection;large-scale photographs will showcase unforgettable experiences born from more than twenty years of close collaboration and cultural exchange. Unfolding in a city-wide takeover, the exhibition culminates
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 12:00:00 EEST | Press release
Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a further step in its Carbon Minimal Inhaler (CMI) journey with the validation of regulatory submissions in Europe for its SITT and ICS/LABA pMDIs. The start of regulatory assessment in Europe marks a significant step towards Chiesi’s transition to carbon minimal pMDIs across its respiratory portfolio, combining innovation with responsibility. This supports the Company’s broader ambition to reduce the environmental impact of respiratory care, while enabling a seamless transition for patients and healthcare professionals. In July 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Chiesi’s beclometasone pMDIs formulated with HFA-152a, marking the first UK approval of this next-generation propellant in a pressurised metered-dose inhaler. Chiesi’s pMDIs are transitioning to HFA-152a, a next-generation propellant classified as non-PFAS* and with low-G
Belkin Expands SoundForm Audio Lineup at IFA 2026, Bringing ANC and Everyday Listening Features to More Accessible Price Points3.9.2026 11:00:00 EEST | Press release
Belkin, a global leader in consumer electronics for over 40 years, today expanded its SoundForm by Belkin audio portfolio with three new products at IFA 2026: SoundForm Isolate, SoundForm Dot and SoundForm Play. The lineup brings features like active noise cancellation (ANC), long battery life and Bluetooth Multipoint connectivity to more accessible price points, with options designed for immersive listening, everyday value and older kids. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903967750/en/ Belkin SoundForm Isolate Buds ANC worn in-ear Leading the new audio range, SoundForm Isolate combines Belkin's most powerful noise cancellation with a secure wing-tip fit, designed for listeners who want greater focus and immersion. SoundForm Dot brings ANC to a more compact and accessible form factor, with both ANC and non-ANC options for everyday listening. Rounding out the lineup, SoundForm Play is designed for kids ages 5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom